Background
The concept of "accelerated" chronic lymphocytic leukemia (CLL) is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of CLL nor its clinical correlates and prognostic impact have been formally defined in large series of patients.
Design and Methods
Tissue biopsies from 100 patients with CLL were analyzed for the size of proliferation centers (PCs) and their proliferation rate as assessed by mitosis count and Ki-67 immunostaining. Histological patterns were correlated with main clinico-biological features and outcome.
Results
The suspicion of disease transformation was the main reason to carry out tissue biopsy, which was performed at a median time of 14 months (range, 0 to 204) from CLL diagnosis. The biopsy showed histological transformation to diffuse large B-cell lymphoma (DLBCL-t) in 22 cases. In the remaining 78 patients, the presence of expanded PCs (broader than a 20x field) and high proliferation rate (either >2.4 mitosis/PC or Ki-67>40%/PC) predicted poor outcome and were selected to define a highly proliferative group. Thus, 23 patients with either expanded PCs or high proliferation rate were considered as having "accelerated" CLL. These patients displayed particular features, including higher serum LDH levels and more frequently elevated ZAP-70 than "non-accelerated" cases. Median survival from biopsy of patients with "nonaccelerated" CLL, "accelerated" CLL and DLBCL-t was 76, 34, and 4.3 months, respectively (p<0.001).
Conclusions
The presence of expanded PCs and/or highly active PCs identifies a group of patients with "accelerated" CLL characterized by an aggressive clinical behavior.
Introduction

Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in
Western countries and is considered to be mainly due to the accumulation of neoplastic CD5+ B lymphocytes with a typical CD19+, CD23+ immunophenotype. 1, 2 According to the WHO classification 3 CLL and small lymphocytic lymphoma (SLL) are considered to be the same disease, primarily involving peripheral blood in the case of CLL and lymph nodes in SLL. A number of parameters, particularly disease stage, lymphocyte doubling time,
IGVH mutational status, ZAP-70 expression and cytogenetics allow to establish the prognosis of the disease at diagnosis. 2, [4] [5] [6] Over the course of the disease, refractoriness to treatment has poor prognosis. Likewise, disease transformation implies a very short survival.
Although considered as a cumulative rather than a proliferative CD5+ B cell neoplasm, CLL cells have a proliferation rate higher than previously recognized, particularly in the lymphoid tissues. 1, 7 Enlarged nodes from patients with CLL show effacement of the lymphoid architecture with a pseudofollicular pattern of pale areas in a dark background of small cells. These pale areas correspond to proliferation centers (PCs) [7] [8] [9] [10] and are predominantly composed of clusters of prolymphocytes and paraimmunoblasts. PCs contain numerous T cells, most of them CD4+, and in some cases a fine network of dendritic cells. and CD71, co-expression of survivin and bcl-2 and also a higher expression of CD20, CD23, and MUM1/IRF-4.
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Histology of the lymph nodes in CLL is heterogeneous and the relationship between different histologic patterns and clinical outcome has been poorly studied. [8] [9] [10] 12, [18] [19] [20] The main reason for this fact is that tissue biopsy is not a standard procedure in the diagnostic workup of patients with CLL. The commonest reason for performing a biopsy is to rule out histological transformation. In general, two major histological patterns in lymph nodes of patients with CLL are recognized: typical CLL involvement and transformation of CLL to DLBCL. However, the existence of no clear-cut histopathological patterns not pertaining into these two broad categories has been known for many years, 10 being poorly characterized and belonging to a kind of "greyzone" in the histopathology of CLL. Although the term "accelerated" CLL is frequently used to describe most of these cases, no histological criteria for identifying this form have been yet proposed and its biological background and clinical significance is largely unknown. In the present study we report criteria to identify "accelerated" CLL, its clinical correlates and prognostic impact. expression was analyzed by flow cytometry in peripheral blood and considered as increased when equal or superior to 30%. The mutational status of the IGVH genes was analyzed in 27 cases following protocols described elsewhere. 4 Clonality was assessed by studying immunoglobulin heavy chain gene (IgH)
Design and Methods
Patients and samples
rearrangement from peripheral blood and paraphine-embedded tissue samples following BIOMED-2 protocols in 12 patients.
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Histological analysis
Tissue samples were analyzed for the presence and size of PCs, and for the proliferation status as assessed by the mitotic index and Ki-67 immunostaining. PCs were defined as the pale areas containing large cells, prolymphocytes and paraimmunoblasts, surrounded by a dark background of small lymphocytes.
PCs were also identified and delineated by a p27 negative staining. 26 PCs were arbitrarily considered as expanded when two or more PCs exceeded a 20x
power field in any of its major dimensions which is approximately equivalent to an area of 0.95 mm 2 in the microscope used to evaluate the samples.
Proliferation inside PCs was determined by both mitotic count and Ki-67
immunostaining and quantified in a total of 8 to 10 PCs per case. In addition, global Ki-67 and p53 were quantified in 8 to 10 40x high power field (hpf) randomly selected in the whole tissue section that included both PCs and small cell component areas. The threshold to consider a p53 staining as positive was 30%.
The diagnosis of transformation to diffuse large cell lymphoma was based on the WHO 2008 criteria. 3 In addition, Ki-67 and p53 immunostainings were performed in these cases and separately analyzed.
Statistical analysis
The correlation between different clinical and biological variables and the histological pattern was performed by means of the Fisher's exact test or nonparametric tests when necessary.
Parameters obtained in the histological analysis, namely the size of PCs and the proliferation index, were correlated with patients survival. To select the optimal cut-off of the quantitative histological variables (mitotic index and Ki-67 expression) for predicting survival, a maximally selected rank statistics test was performed using the Maxstat package (R statistical package, v. 2.8.1, Vienna, Austria) 27 and the cut-off was ultimately delimitated by the Kaplan and Meier method. 28 To minimize a possible selection bias, survival was calculated from the time of biopsy and analyzed according to the method described by Kaplan and Meier and the curves compared by the log-rank test. 29 All prognostic variables in the univariate analysis with enough number of cases available were included in the multivariate analysis using the stepwise proportional hazard Cox regression model. 30 All statistical tests were two-sided and the significance level was 0.05.
Results
Patients and tissue biopsies
The main initial clinico-biological characteristics of the patients are detailed in Table 1 . 
Impact of expanded and proliferating PCs in the patients' outcome
From the 100 patients included in this series, the diagnosis of CLL was established in 78 cases, whereas the remaining 22 patients were diagnosed with transformation into DLBCL (DLBCL-t).
In the 78 cases included in this study not showing disease transformation to DLBCL, PCs were observed in 69 and were absent in 9. In the latter, isolated prolymphocytes and paraimmunoblasts could be recognized at high magnification and corresponded to the diffuse CLL pattern described by K. p=0.014) ( Figure 1C ). Global Ki-67 expression analysis did not yield any significant cut-off for survival. Among patients with expanded PCs, 65% had either a mitotic rate >2.4 or Ki67 >40% within the PCs.
Patients with any of the histological parameters with adverse prognosis, namely expanded PCs, mitosis count > 2.4 or Ki67 >40% per PC, were considered as having an "accelerated" CLL (n=23). The remaining patients with no adverse histological features were considered as having a "non-accelerated" CLL (n=55). The main histological features of patients with "non-accelerated" CLL, "accelerated" CLL, and DLBCL-t are summarized in Table 2 . Representative histological images are shown in Figure 2 . Among other histological variables studied, the global Ki-67 immunostaining was higher in DLBCL-t than in "accelerated" CLL and "non-accelerated" CLL (mean+/-SD of Ki-67: 68%+/-14 vs. 12%+/-8.5 vs. 2%+/-2.4, respectively; p= 0.001). In addition, p53 was positive by immunostaining in 67%, 18% and 2% of patients with DLBCL-t, "accelerated" CLL and "non-accelerated" CLL, respectively (p<0.0001).
Analysis of clonality
To ascertain whether tissue samples of "accelerated" CLL were clonally related to the CLL neoplastic lymphocytes from peripheral blood, IGVH rearrangement was analyzed in 8 patients. The same kind of analysis was also performed in 4 patients with DLBCL-t. All patients with "accelerated" CLL showed the same clonal rearrangement in tissue and peripheral blood. In contrast, one out of four DLBCL-t was clonally unrelated.
Clinico-biological features and outcome of "accelerated" CLL
The main characteristics of the patients at the time of tissue biopsy are listed in Table 3 . Patients with "accelerated" CLL presented similar characteristics compared to the "non-accelerated" CLL cases regarding the presence of B symptoms, performance status, bulky disease or clinical stage. However, patients with "accelerated" CLL" had higher serum LDH levels and more elevated ZAP-70 expression (p<0.01), than patients with "non-accelerated" CLL.
On the other hand, patients with DLBCL-t displayed more frequently poor performance status and B symptoms than "accelerated" and "non-accelerated" CLL. It is of note that in 9 out of 22 cases (41%) with DLBCL-t, disease transformation was diagnosed in an extranodal site in contrast to patients with CLL (either "accelerated" or "non-accelerated"), in whom only one extranodal case (breast mass) was observed (p<0.001). Serum LDH levels were found progressively increased from "non-accelerated" CLL, "accelerated" CLL and DLBCL-t (mean values+/-SD in IU/L: 455±194 vs. 543±198 vs. 820±538, respectively, p=0.008). Among the three histological groups, no differences in the distribution of poor risk cytogenetic alterations (17p and 11q deletions) were observed.
Time from diagnosis to tissue biopsy was longer in DLBCL-t than in CLL (mean:
69 vs. 45 months, respectively, p=0.001). Whilst 9 out of the 23 "accelerated" CLL cases were observed at diagnosis, only 2 out of the 22 DLBCL-t cases were observed at that moment. Forty-five percent of patients with "accelerated" CLL were diagnosed before starting treatment.
In two patients with "accelerated" CLL new tissue biopsies were obtained during follow-up. In one case the pattern of "accelerated" CLL remained stable over time, whereas in the second one a transformation to DLBCL was demonstrated after 5 years.
The presence of expanded or highly proliferative PCs did not influence the treatment decision. Treatment for "accelerated" CLL cases varied over time.
Whereas 52% of patients received doxorubicin-containing regimens, 30% of patients were treated with purine analogs alone or in combination. In contrast, 73% of patients diagnosed with DLBCL-t were treated with doxorubicincontaining regimens. Intensification with stem cell transplantation was carried out in 16 patients, including 6 patients with "non-accelerated" CLL, 6 patients with "accelerated" CLL, and 4 patients with DLBCL-t. syndrome was also predictive for survival in the whole series and in the DLBCL-t and "accelerated" histological subsets.
In a multivariate survival analysis, the histological subtype ("non accelerated"
vs. "accelerated" vs. DLBCL-t) (p=<0.001; RR 2.7 and 5 .5 for "accelerated"
and DLBCL-t vs. "non-accelerated", respectively) together with age (p=<0.001; p<0.001; RR 3.9) were the most important prognostic variables in the global series (analysis performed in 94 patients in whom all the data were available).
When the same analysis was performed after excluding patients with DLBCL-t, the histological subtype ("non accelerated" vs. "accelerated") (p=0.007; RR 2.5) along with age (p=0.002; RR 1.05) and M.D. Anderson score for Richter's syndrome (p=0.001; RR 3.6) maintained its prognostic importance.
Discussion
Increasing data suggest that PCs have an important role in the biology of CLL as they constitute its proliferative compartment. 1, 7 However, the complexity of PCs microenvironment has not been completely elucidated. 32 In addition, the clinical significance of the number and size of PCs, where proliferation of CLL takes place, remains to be established. Historically, Lennert 10,31 recognized a histological "tumor-forming" type of CLL characterized by an excessive prolymphocyte proliferation, resulting in large lighter regions when examined under the microscope. These "tumor-forming" type CLL cases were considered to convey poor prognosis but no clinical studies were performed at that time.
Since then, other studies have attempted to correlate histological characteristics of lymph nodes with prognosis but most of these reports are flawed by a number of reasons, including lack of immunophenotypic studies, 8, 9, 20 limited number of subjects and short follow-up. 12, 18, 19 In our series, PCs were found in 88% of the biopsies and their size and proliferation activity were important predictors for survival from the time of biopsy. Thus, patients with either PCs broader than 20x hpf or an increased proliferation rate within PCs as assessed by a mitotic count >2.4 per PC and/or Ki-67 index >40% per PC, have a particularly poor outcome.
From a clinical point of view, the features of "non-accelerated" and "accelerated" CLL patients were comparable except for the observed higher frequency of elevated LDH levels and ZAP-70 expression in "accelerated"
cases. While the latter were also clinically undistinguishable from DLBCL-t cases, "accelerated" CLL was observed in around half of the cases early on the clinical course of the disease, in untreated patients and mainly with nodal involvement. On the contrary, DLBCL-t tended to occur later in the course of the disease, usually in pretreated patients and frequently displaying extranodal involvement. Moreover, survival curves for "accelerated" CLL and DLBCL-t were different, although this difference did not reach statistical significance (34 months vs. 4 months, p=0.07).
A predominance of poor prognostic markers was found in our series compared to standard CLL. 33, 34 This is not unexpected since the main reason to perform a biopsy was the suspicion of histological transformation. An increasing number of p53 positive cases were found comparing "non-accelerated" CLL to In conclusion, in this study we present easy-to-apply histological criteria to identify "accelerated" CLL and show that this form of disease is associated with poor prognostic features and short survival. Further studies are needed to clarify the molecular events behind this form of the disease, its boundaries with disease transformation, and the more appropriate treatment approach for these patients. 
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